Phase II Trial of SBRT and Androgen Deprivation for Oligometastases in Prostate Cancer

Conde-Moreno, Antonio José; López, F.; Hervás, A.; Morillo, V.; Méndez, A.; Puertas, M.D.M.; Albarran, J. Valero; Iturriaga, Alfonso Gómez de; Rico, M.; Torre, M. L. Vázquez de la; Ots, P.M. Samper; Romasanta, Luis A. Pérez; Peidro, J. Pastor; Ibáñez, Carolina; Ferrer, F.; Zapatero, A.; Anchuelo, J.; Rodríguez, A.; Albiach, C. Ferrer

doi:10.1016/j.ijrobp.2021.07.151

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is currently no available clinical evidence from randomized phase III trials assessing the role of ADT in the scenario of node oligorecurrent PCa. However, information from the SBRT-SG 05 prospective multicentre phase II trial provides insight into the subject [ 48 ]. This study examined the effectiveness of SBRT and ADT in patients with oligorecurrent hormone-sensitive prostate cancer.…”

Section: Combined Rt and Systemic Therapymentioning

confidence: 99%

“…However, it should be noted that an important limitation is the higher use of ADT in ENRT in both De Blesser and GETUG P07 trials. Moreover, the SBRT-SG05 study [ 48 ], which evaluated the efficacy of SBRT and ADT, observed a median DPFS of 54.2 months (95% CI = 48.2–60.3), which is not notably distinct from the results seen with ENRT.…”

Section: Volume Of Treatment and Rt Scheme: N1 Vs M1a? Role Of Electi...mentioning

confidence: 99%

See 1 more Smart Citation

Node Oligorecurrence in Prostate Cancer: A Challenge

Zapatero,

Conde Moreno,

Barrado Los Arcos

et al. 2023

Cancers

View full text Add to dashboard Cite

Within the oligometastatic state, oligorecurrent lymph node disease in prostate cancer represents an interesting clinical entity characterized by a relatively indolent biology that makes it unique: it can be treated radically, and its treatment is usually associated with a long period of control and excellent survival. Additionally, it is an emergent situation that we are facing more frequently mainly due to (a) the incorporation into clinical practice of the PSMA-PET that provides strikingly increased superior images in comparison to conventional imaging, with higher sensitivity and specificity; (b) the higher detection rates of bone and node disease with extremely low levels of PSA; and (c) the availability of high-precision technology in radiotherapy treatments with the incorporation of stereotaxic body radiotherapy (SBRT) or stereotaxic ablative radiotherapy (SABR) technology that allows the safe administration of high doses of radiation in a very limited number of fractions with low toxicity and excellent tolerance. This approach of new image-guided patient management is compelling for doctors and patients since it can potentially contribute to improving the clinical outcome. In this work, we discuss the available evidence, areas of debate, and potential future directions concerning the utilization of new imaging-guided SBRT for the treatment of nodal recurrence in prostate cancer.

show abstract

Section: Combined Rt and Systemic Therapymentioning

confidence: 99%

Section: Volume Of Treatment and Rt Scheme: N1 Vs M1a? Role Of Electi...mentioning

confidence: 99%